Skip to content

Alpine farming and the diversity of the human nasal microbiome - The ALM feasibility study

Ecological exposure through alpine farming: a feasibility study on the diversity of the human nasal microbiome in "Alm-Naive" Persons

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN65561496
Enrollment
15
Registered
2025-10-23
Start date
2022-06-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physiological, immunological, and psychological effects of a seven-day nature-based lifestyle intervention in healthy urban adults. Other

Interventions

The intervention comprises a seven-day immersive exposure to a traditional alpine agrarian environment in the Riedingtal Valley, Salzburg, Austria. This setting—characterized by elevated microbial bio

Sponsors

Paracelsus Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age: 18-65 years 2. Gender: women and men 3. “Alm-naïve”: No previous residence, occupation or internship in an agricultural environment 4. No exposure to: Agricultural jobs (professional/residential) in the last 5 years, Agricultural schools/training, Shared living with farmers

Exclusion criteria

Exclusion criteria: 1. Uncontrolled diseases: 1.1. Metabolic: fasting blood sugar = 140 mg/dL 1.2. Cardiovascular: RR systolic = 180 mmHg, diastolic = 110 mmHg 1.3. Psychiatric: PHQ-9 > 9 (depressive symptoms); Immunological: Pathological disorders of the immune system 2. Medication use: Antibiotics; cortisone preparations, immunosuppressants 3. Active cancer or therapy within the last 5 years 4. Substance abuse: Drugs, alcohol, nicotine

Design outcomes

Primary

MeasureTime frame
Human nasal microbiome diversity, assessed via 16S rRNA gene sequencing at baseline (t0) and again after the intervention on day 7

Secondary

MeasureTime frame
At baseline (t0) and again after the intervention on day 7: 1. Lipid metabolism markers (HDL cholesterol, non-HDL cholesterol, total cholesterol, triglycerides) 2. Differential blood count 3. Inflammatory markers (C-reactive protein and interleukin-6) 4. Chester Step Test to estimate VO2max 5. Subjective wellbeing and quality of life (WHO-5 Wellbeing Index , EQ-5D-5L visual analogue scale, Nature Relatedness Scale )

Countries

Austria

Contacts

Public ContactArnulf Hartl
arnulf.hartl@pmu.ac.at+43 (0)662 2420 80530

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026